U.S. Multi Cancer Early Detection Market Size & Outlook
U.S. multi cancer early detection market, 2018-2030 (US$M)
Related Markets
U.S. multi cancer early detection market highlights
- The U.S. multi cancer early detection market generated a revenue of USD 250.7 million in 2022 and is expected to reach USD 1,189.2 million by 2030.
- The U.S. market is expected to grow at a CAGR of 21.5% from 2023 to 2030.
- In terms of segment, gene panel, ldt & others was the largest revenue generating type in 2022.
- Liquid Biopsy is the most lucrative type segment registering the fastest growth during the forecast period.
Multi cancer early detection market data book summary
| Market revenue in 2022 | USD 250.7 million |
| Market revenue in 2030 | USD 1,189.2 million |
| Growth rate | 21.5% (CAGR from 2022 to 2030) |
| Largest segment | Gene panel, ldt & others |
| Fastest growing segment | Liquid Biopsy |
| Historical data | 2018 - 2021 |
| Base year | 2022 |
| Forecast period | 2023 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Liquid Biopsy, Gene Panel, LDT & Others |
| Key market players worldwide | Illumina Inc, Exact Sciences Corp, Foundation Medicine, Guardant Health Inc, Burning Rock Biotech Ltd ADR, Freenome, AnchorDx, GeneCast, Elypta |
Other key industry trends
- In terms of revenue, U.S. accounted for 29.3% of the global multi cancer early detection market in 2022.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In North America, U.S. multi cancer early detection market is projected to lead the regional market in terms of revenue in 2030.
- U.S. is the fastest growing regional market in North America and is projected to reach USD 1,189.2 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Multi Cancer Early Detection Market Scope
Multi Cancer Early Detection Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
U.S. multi cancer early detection market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to multi cancer early detection market will help companies and investors design strategic landscapes.
Gene panel, ldt & others was the largest segment with a revenue share of 97.89% in 2022. Horizon Databook has segmented the U.S. multi cancer early detection market based on liquid biopsy, gene panel, ldt & others covering the revenue growth of each sub-segment from 2018 to 2030.
The U.S. is the largest market for MCED tests in North America, holding over 88.9% of revenue share in 2022. Owing to high cancer prevalence in the country, there is rapid adoption of cancer diagnostic tests.
Furthermore, significant technological advancements, increasing number of FDA approvals for MCED tests, and competition among biotechnology companies are projected to boost market growth over the forecast period.
According to the American Cancer Society, in 2022, 236,740 people were estimated to be diagnosed with non-small cell lung cancer, the most common form of lung cancer, in the U.S. Overall, around 1 in 17 men and 1 in 15 women are at risk of developing lung cancer in their lifetime.
Reasons to subscribe to U.S. multi cancer early detection market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of U.S. multi cancer early detection market databook
-
Our clientele includes a mix of multi cancer early detection market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the U.S. multi cancer early detection market , including forecasts for subscribers. This country databook contains high-level insights into U.S. multi cancer early detection market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
U.S. multi cancer early detection market size, by type, 2018-2030 (US$M)
U.S. Multi Cancer Early Detection Market Outlook Share, 2022 & 2030 (US$M)
Related industry reports
Related regional statistics
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
